Review Identifies ATG5 as Context-Dependent Switch in Cancer Drug Resistance

Autophagy-Related Gene 5, commonly designated as ATG5, operates as a context-dependent molecular switch that reshapes the balance between cellular adaptation and therapeutic vulnerability, according to a comprehensive review published in Cancer Cell International. In their published synthesis, the authors examine ATG5 as a central regulator of cellular autophagy that functions as a critical node positioned at the direct intersection of autophagy, apoptosis, and therapy resistance. Beyond its canonical role in autophagosome formation, ATG5 engages key apoptotic regulators and interacts with multiple signaling pathways to shape cancer cell fate. By evaluating these molecular intersections, the review outlines how ATG5 governs cellular survival and drug response mechanisms across diverse cancer types.

Although ATG5 is ubiquitously expressed throughout normal tissues, the review emphasizes that its biological impact in malignancy is highly context specific. In numerous solid tumors, elevated ATG5 expression is clinically associated with worse overall survival and increased resistance to therapy. Conversely, in other cancer types, elevated ATG5 expression predicts improved outcomes rather than disease progression. This striking divergence reflects the dual capacity of ATG5 to act either as a tumor suppressor or as a tumor-protective factor depending on the specific cancer setting. Consequently, the prognostic and functional significance of ATG5 expression varies considerably depending on the tumor type and its distinct cellular context.

To clarify how ATG5 influences therapy outcomes, the review maps the intricate signaling networks that crosstalk with ATG5 to sustain autophagy-dependent survival in cancer cells. The authors detail how these interconnected molecular pathways rewire cellular stress responses to promote drug resistance across multiple therapeutic modalities. In addition, the synthesis delineates the regulatory mechanisms and specific protein-interaction interfaces that maintain this survival dependency within tumor cells. By characterizing these signaling networks and interaction interfaces, the authors outline the specific treatment contexts in which the pharmacological inhibition of autophagy is most likely to be therapeutically effective against resistant cancers.

Together, these findings position ATG5 as both a critical mechanistic linchpin in therapy resistance and an important translational opportunity for cancer research. The authors conclude that translating these insights into effective clinical interventions requires precisely defining which tumors are functionally dependent on ATG5-mediated autophagy. In addition, identifying the specific interactome nodes that sustain this dependent state represents an essential requirement for therapeutic progress. Ultimately, establishing these molecular characteristics will be vital for developing biomarker-driven strategies capable of converting ATG5 dependence into an actionable therapeutic vulnerability in cancer patients undergoing treatment.

Subject of Research: Role of ATG5 in cancer therapy resistance

Article Title: Autophagy-related gene 5 in drug resistance: a comprehensive review

Article References: Ghilane, F., Attouahri, F. Z., El Mzibri, M., Al Abdulmonem, W., El Btaouri, H., Ababou, M., & Bouyahya, A. (2026). Autophagy-related gene 5 in drug resistance: a comprehensive review. Cancer Cell International. https://doi.org/10.1186/s12935-026-04488-9

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04488-9

Keywords: ATG5, autophagy, drug resistance, cancer research, apoptosis, oncology, therapy resistance, solid tumors, Autophagy-related, gene, drug, resistance